cyclin δ-1 Activators
Cyclin D1Cyclin D1 Activators are a diverse array of chemical compounds that indirectly elevate the functional activity of Cyclin D1 through their targeted interaction with cyclin-dependent kinases (CDKs). For instance, Palbociclib, Ribociclib, and Abemaciclib, all inhibitors of CDK4/6, work by blocking the phosphorylation of the retinoblastoma protein, resulting in G1 arrest. This mechanism indirectly upholds the Cyclin D1-CDK4/6 complex in an active state, crucial for the cell cycle progression from G1 to the S phase. Similarly, Roscovitine, while it is a more general CDK inhibitor, can favor Cyclin D1 activity by modulating the CDK activity equilibrium in favor of Cyclin D1-CDK4/6 complex formation and function. Flavopiridol and Milciclib, by inhibiting various CDKs, including those competing with CDK4/6, indirectly enhance the activity of the Cyclin D1-CDK4/6 complex, pivotal for the G1-S phase transition.
Furthermore, compounds such as Trilaciclib, PD 0332991, and LEE011 validate their Cyclin D1 activating capacity by stabilizing the Cyclin D1-CDK4/6 complex, thereby promoting cell cycle progression in the G1 phase. Dinaciclib and SNS-032, through their potent inhibition of a broad spectrum of CDKs, inadvertently shift cellular equilibrium to augment the activity of Cyclin D1 by fostering its association with CDK4/6. LY2835219, or Abemaciclib, completes this suite of activators by selectively inhibiting CDK4/6, thereby maintaining an active Cyclin D1-CDK4/6 complex. This array of chemical activators, through their unique and specific interactions with cellular kinases, collectively enhance the functional role of Cyclin D1, a key regulator of cell cycle progression, without directly influencing its expression levels.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of CDK4/6, kinases that phosphorylate and inactivate the retinoblastoma protein. Inhibition of these kinases by Palbociclib leads to cell cycle arrest at G1, which indirectly enhances the activity of Cyclin D1 by prolonging its association with CDK4/6, facilitating cell cycle progression in cells where Cyclin D1 is functional. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a purine analogue that selectively inhibits CDKs. While primarily acting as an inhibitor for CDK1, CDK2, and CDK7, it can enhance Cyclin D1 activity by shifting CDK equilibrium, promoting Cyclin D1-CDK4/6 complex formation and activity, which is critical for G1-S phase transition. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib specifically inhibits CDK4/6, similar to Palbociclib, and by doing so, it increases the availability of CDK4/6 for complexing with Cyclin D1, which enhances the functional activity of Cyclin D1 in driving the G1-S phase transition. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is another CDK4/6 inhibitor that, by preventing the phosphorylation of the retinoblastoma protein, indirectly maintains the Cyclin D1-CDK4/6 complex in an active state, contributing to the cell cycle progression from G1 to S phase. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol is a potent CDK inhibitor with a broad spectrum of targets, including CDK1, CDK2, CDK4, CDK6, and CDK7. It can indirectly increase Cyclin D1 activity by inhibiting competitive CDKs and shifting the balance towards Cyclin D1-CDK4/6 complex functionality. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
SNS-032 is a selective inhibitor of CDK2, CDK7, and CDK9, which can indirectly enhance Cyclin D1 activity by shifting the balance of CDK activity towards Cyclin D1-CDK4/6 complexes, critical for the G1 phase of the cell cycle. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib strongly inhibits several CDKs including CDK1, CDK2, CDK5, and CDK9, which can lead to an indirect enhancement of Cyclin D1 activity by promoting its association with CDK4/6, thus facilitating G1-S phase cell cycle progression. | ||||||